A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00617604
First received: February 6, 2008
Last updated: January 5, 2016
Last verified: January 2016
  Purpose
The purpose of this study is to determine whether alefacept is effective and well tolerated when used with a combination of tacrolimus, mycophenolate mofetil and steroids versus a combination therapy of placebo, tacrolimus and steroids in the prevention of kidney transplant rejection.

Condition Intervention Phase
De Novo Kidney Transplantation
Drug: Alefacept
Drug: placebo
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Steroids
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy and Safety of Alefacept in Combination With Tacrolimus, Mycophenolate Mofetil and Steroids in de Novo Kidney Transplantation - a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Percentage of Participants With Biopsy-confirmed Acute T-cell Mediated Rejection at Month 6 Assessed by Local Review [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification:

    • Grade IA: significant interstitial infiltration (>25% parenchyma affected) and foci of moderate tubulitis;
    • Grade IB: significant interstitial infiltration (>25% parenchyma affected) and foci of severe tubulitis;
    • Grade IIA: mild to moderate intimal arteritis;
    • Grade IIB: severe intimal arteritis comprising >25% of the luminal area;
    • Grade III: "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation.

    A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1.

    The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.



Secondary Outcome Measures:
  • Percentage of Participants With Biopsy Confirmed Antibody-Mediated Acute Rejection at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification:

    Acute antibody-mediated rejection - documented anti-donor antibody ('suspicious for' if antibody not demonstrated):

    • Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation;
    • Grade II: capillary-margination and/or thromboses, C4d+
    • Grade III: arterial - v3, C4d+.

    A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1.

    The Kaplan-Meier estimate of biopsy-confirmed antibody-mediated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.


  • Percentage of Participants With Biopsy Confirmed Acute Rejection (T-Cell Mediated or Antibody Mediated) at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1.

    The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated or antibody-mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.


  • Percentage of Participants With Biopsy Confirmed Acute Mixed T-Cell Mediated and Antibody-Mediated Rejection at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Biopsies were graded by the clinical site pathologist.according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1.

    The Kaplan-Meier estimate of biopsy-confirmed acute mixed T-cell mediated and antibody-mediated rejections within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.


  • Percentage of Participants With Acute Rejection Diagnosed by Signs and Symptoms at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Acute rejection diagnosed by signs and symptoms, including biopsy-confirmed or suspected (not confirmed by biopsy - i.e. no biopsy was performed or biopsy did not confirm an acute T-cell mediated rejection). The Kaplan-Meier estimate of acute rejection diagnosed by signs and symptoms within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.

  • Percentage of Participants With Clinically Treated Acute Rejection at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Patients who received immunosuppressive medications for the treatment of suspected or biopsy-confirmed acute rejections were considered to have a clinically-treated acute rejection. The Kaplan-Meier estimate of clinically treated acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.

  • Percentage of Participants With Steroid-resistant Acute Rejection at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    A steroid-resistant acute rejection is defined as a rejection episode which did not resolve following treatment with corticosteroids. In the case that a rejection episode was not treated with corticosteroids first but only with antibodies, it was included in this category.

    The Kaplan-Meier estimate of steroid-resistant acute rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.


  • Percentage of Participants With Biopsy-Confirmed Acute T-cell Mediated Rejection as Assessed by Central Review at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Biopsies were graded by the central reviewer according to the Banff 97/05 updated histological classification. A biopsy confirmed acute rejection was an event of suspected acute rejection confirmed by a graft biopsy result of Banff grade ≥ 1.

    The Kaplan-Meier estimate of biopsy-confirmed acute T-cell mediated rejection within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow up visit.


  • Patient Survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Patient survival is any participant known to be alive at Month 6. The Kaplan-Meier estimate of patient survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment.

  • Graft Survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Graft survival was defined as any participant who was known to have a functioning graft (i.e., not graft loss) at 6 months. Graft loss is defined as re-transplantation, nephrectomy, death or as dialysis ongoing at end of study or at discontinuation of the participant unless superseded by follow-up information.

    The Kaplan-Meier estimate of graft survival within the first 6 months following transplantation is reported. Participants lost to follow-up were censored at the time of last assessment.


  • Maximum Histological Grade of All Biopsies After Local Review [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    The grade of acute rejection was classified according to Banff 97/05 updated version. If a patient had more than 1 rejection episode, the episode with the most severe grade was used.

    Acute T-cell mediated rejection:

    • Grade IA: significant interstitial infiltration (>25% parenchyma affected) and foci of moderate tubulitis;
    • Grade IB: significant interstitial infiltration (>25% parenchyma affected) and foci of severe tubulitis;
    • Grade IIA: mild to moderate intimal arteritis;
    • Grade IIB: severe intimal arteritis comprising >25% of the luminal area;
    • Grade III: "transmural" arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation.

    Acute antibody-mediated rejection:

    • Grade I: acute tubular necrosis-like - complement split product positive (C4d+), minimal inflammation;
    • Grade II: capillary-margination and/or thromboses, C4d+
    • Grade III: arterial - v3, C4d+.

  • Percentage of Participants With Anti-Lymphocyte Antibody Therapy for Treatment of Rejection at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The Kaplan-Meier estimate of anti-lymphocyte antibody therapy for acute rejection (clinically-treated or biopsy-confirmed) within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.

  • Change From Month 1 in Serum Creatinine [ Time Frame: Month 1, 3, and 6 ] [ Designated as safety issue: No ]
  • Change From Month 1 in Glomerular Filtration Rate (GFR) [ Time Frame: Month 1, 3, and 6 ] [ Designated as safety issue: No ]
    The GFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula.

  • Change From Month 1 in Creatinine Clearance [ Time Frame: Month 1, 3, and 6 ] [ Designated as safety issue: No ]
    The creatinine clearance was calculated according to the Cockcroft-Gault formula.

  • GFR Measured by Iothalamate Clearance at Month 6 [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
    GFR measured using the iothalamate clearance method and determined by a central laboratory.

  • Percentage of Participants With Efficacy Failure at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Efficacy failure is defined as death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading or lost to follow-up.

    The Kaplan-Meier estimate of efficacy failure within the first 6 months following transplantation is reported.


  • Percentage of Participants With Delayed Graft Function [ Time Frame: 1 week ] [ Designated as safety issue: No ]
    Delayed graft function was defined as the requirement for dialysis within the first week post-transplant.

  • Percentage of Participants With Treatment Failure at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Treatment failure is defined as efficacy failure (death, graft loss, biopsy-confirmed acute T-cell mediated rejection assessed by local reading, lost to follow-up) or early discontinuation of alefacept/placebo at any time (during the 12-week administration period) for any reason. The Kaplan-Meier estimate of treatment failure within the first 6 months following transplantation is reported. Participants lost to follow-up or with missing outcomes were censored at their last follow-up visit.

  • Number of Participants With Adverse Events [ Time Frame: 6 Months ] [ Designated as safety issue: No ]

    Causally related was defined as adverse events (AEs) assessed by the Investigator as possibly or probably related to study drug or records where the relationship was missing.

    A serious adverse event (SAE) was any untoward medical occurrence that, at any dose:

    • Resulted in death.
    • Was life-threatening.
    • Resulted in persistent or significant disability/incapacity.
    • Resulted in congenital anomaly or birth defect.
    • Required patient hospitalization or led to prolongation of hospitalization
    • Was considered a medically important event.

    All rejections and any BK virus, Epstein Barr virus and/or cytomegalovirus infection had to be reported as an SAE



Enrollment: 218
Study Start Date: December 2007
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
Drug: placebo
IV and subcutaneous injection
Drug: Tacrolimus
The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
Drug: Mycophenolate Mofetil
Mycophenolic mofetil was administered as 750 mg twice per day orally
Drug: Steroids

Methylprednisolone or equivalent:

Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus

Prednisone or equivalent:

Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally

Experimental: Alefacept
Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
Drug: Alefacept
IV and subcutaneous injection
Other Name: Amevive
Drug: Tacrolimus
The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
Drug: Mycophenolate Mofetil
Mycophenolic mofetil was administered as 750 mg twice per day orally
Drug: Steroids

Methylprednisolone or equivalent:

Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus

Prednisone or equivalent:

Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally


  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject with end stage kidney disease who is a suitable candidate for primary kidney transplantation or retransplantation
  • Male or female subject at least 18 years of age and younger than 65 years
  • Subject receiving a kidney transplant from a non-human leucocyte antigen (HLA) identical living donor or deceased HLA identical/non-HLA identical donor between 5 and 59 years of age with compatible ABO blood type (Blood group system A, B, AB and 0)

Exclusion Criteria:

  • Subject has a panel reactivity antibody grade > 20% in the previous 6 months and/or had had a previous graft survival shorter than 1 year due to immunological reasons
  • Subject received a kidney transplant from a non-heart beating donor
  • Subject has received a kidney transplant from a 50 - 59 year old donor with two of the following three factors: history of hypertension, cerebrovascular accident as cause of death, final pre-procurement serum creatinine > 1.5 mg/dL (united network for organ sharing [UNOS] expanded criteria donor)
  • Cold ischemia time of the donor kidney is ≥ 30 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00617604

  Show 33 Study Locations
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Chair: Central Contact Astellas Pharma Europe B.V.
  More Information

Additional Information:
No publications provided

Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT00617604     History of Changes
Other Study ID Numbers: 0485-CL-E201  2007-002092-14 
Study First Received: February 6, 2008
Results First Received: January 5, 2016
Last Updated: January 5, 2016
Health Authority: Austria: Agency for Health and Food Safety
Belgium: Federal Agency for Medicinal Products and Health Products
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Italy: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Ministry of Health
Spain: Ministry of Health
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Astellas Pharma Inc:
kidney transplant
alefacept

Additional relevant MeSH terms:
Alefacept
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Antibiotics, Antineoplastic
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on February 07, 2016